Myomo (MYO) 10-K 12 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 06, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	MYO
Entity Registrant Name	MYOMO INC
Entity Central Index Key	0001369290
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		17,083,715
Entity Public Float			$ 32,962,311

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 6,540,794	$ 12,959,373
Accounts receivable, net	382,258	297,039
Inventories, net	256,149	201,155
Prepaid expenses and other	695,276	388,275
Total Current Assets	7,874,477	13,845,842
Restricted cash	75,000	52,000
Deferred offering costs	144,582
Equipment, net	187,513	77,150
Total Assets	8,281,572	13,974,992
Current Liabilities:
Accounts payable and other accrued expenses	1,743,427	1,277,236
Derivative liabilities	3,661	39,930
Deferred revenue	1,990	61,288
Customer advance payments	106,609	106,718
Total Current Liabilities	1,855,687	1,485,172
Deferred revenue, net of current portion		44,042
Total Liabilities	1,855,687	1,529,214
Commitments and Contingencies
Stockholders’ Equity:
Common stock par value $0.0001 per share 100,000,000 shares authorized; 12,450,187 and 11,139,667 shares issued as of December 31, 2018 and 2017, respectively, and 12,449,379 and 11,138,859 shares outstanding as of December 31, 2018 and 2017, respectively.	1,245	1,114
Undesignated preferred stock par value $0.0001 per share; 25,000,000 authorized at December 31, 2018 and 2017. No shares issued or outstanding
Additional paid-in capital	51,720,630	47,423,915
Accumulated deficit	(45,289,526)	(34,972,787)
Treasury stock, at cost; 808 shares of common stock	(6,464)	(6,464)
Total Stockholders’ Equity	6,425,885	12,445,778
Total Liabilities and Stockholders’ Equity	$ 8,281,572	$ 13,974,992

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,450,187	11,139,667
Common stock, shares outstanding	12,449,379	11,138,859
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury shares at cost	808	808

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 2,444,104	$ 1,558,866
Cost of revenue	728,279	505,280
Gross margin	1,715,825	1,053,586
Operating expenses:
Research and development	1,838,633	1,751,731
Selling, general and administrative	10,405,609	5,849,969
Total operating expenses	12,244,242	7,601,700
Loss from operations	(10,528,417)	(6,548,114)
Other expense (income)
Loss on early extinguishment of debt		135,244
Change in fair value of derivative liabilities	(36,269)	(116,795)
Debt discount on convertible notes		5,172,000
Interest (income) and other expense, net	(175,409)	358,916
Total other expense (income)	(211,678)	5,549,365
Net loss	(10,316,739)	(12,097,479)
Deemed dividend – accreted preferred stock		(274,011)
Cumulative dividend to Series B-1 preferred stockholders		(287,779)
Net loss available to common stockholders	$ (10,316,739)	$ (12,659,269)
Weighted average number of common shares outstanding:
Basic and diluted	12,292,402	4,317,864
Net loss per share available to common stockholders:
Basic and diluted	$ (0.84)	$ (2.93)

Statements of Changes in Redeem

Statements of Changes in Redeemable and Convertible Preferred Stock and Stockholders' (Deficiency) Equity - USD ($)	Total	Series B-1 Convertible Preferred Stock [Member]	Series A-1 Convertible Preferred Stock [Member]	Common Stock [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	IPO [Member]	IPO [Member]Common Stock [Member]	IPO [Member]Additional Paid-in Capital [Member]	Over-allotment Option [Member]	Over-allotment Option [Member]Common Stock [Member]	Over-allotment Option [Member]Additional Paid-in Capital [Member]
Beginning balance at Dec. 31, 2016	$ (17,530,456)	$ 8,174,693	$ 4,497,548	$ 112	$ (22,875,308)	$ (6,464)	$ 5,351,204
Beginning balance, shares at Dec. 31, 2016		1,662,104	960,083	1,124,080		808
Accretion of preferred stock	(274,011)	$ 31,493	$ 242,518				(274,011)
Proceeds from offering costs								$ 3,930,078	$ 67	$ 3,930,011	$ 10,407,706	$ 480	$ 10,407,226
Proceeds from offering costs, shares									665,498			4,801,250
Proceeds from private placement, net of offering costs of $2,500	2,922,885			$ 56			2,922,829
Proceeds from private placement, net of offering costs of $2,500, shares				557,216
Conversion of Series A-1 and Series B-1 convertible preferred stock into common stock	12,946,252	$ (8,206,186)	$ (4,740,066)	$ 262			12,945,990
Conversion of Series A-1 and Series B-1 convertible preferred stock into common stock, Shares		(1,662,104)	(960,083)	2,622,187
Conversion of convertible promissory notes into common stock	5,467,389			$ 106			5,467,283
Conversion of convertible promissory notes into common stock, shares				1,055,430
Fair value of warrants issued with convertible promissory notes	5,172,000						5,172,000
Warrants issued to IPO selling agent deemed to be derivative liability	(156,725)						(156,725)
Common stock issued for the exercise of common stock options	$ 26,954			$ 8			26,946
Common stock issued for the exercise of common stock options, shares	80,085			80,085
Common stock issued for the exercise of warrants	$ 102,660			$ 3			102,657
Common stock issued for the exercise of warrants, shares				34,800
Restricted stock vested, shares				312
Shares of common stock issued for services	30,000						30,000
Shares of common stock issued for services, shares				4,000
Shares of common stock issued for repayment of promissory notes	1,217,172			$ 19			1,217,153
Shares of common stock issued for repayment of promissory notes, shares				193,509
Additional shares issued pursuant to software license agreement	1,845			$ 1			1,844
Additional shares issued pursuant to software license agreement, shares				492
Stock-based compensation	279,508						279,508
Net loss	(12,097,479)				(12,097,479)
Ending balance at Dec. 31, 2017	12,445,778			$ 1,114	(34,972,787)	$ (6,464)	47,423,915
Ending balance, shares at Dec. 31, 2017				11,138,859		808
Common stock issued upon vesting of restricted stockunits, net of 22,819 shares withheld for employee taxes	(74,213)			$ 4			(74,217)
Common stock issued upon vesting of restricted stock units, Shares				42,781
Common stock issued for the exercise of common stock options	$ 2						2
Common stock issued for the exercise of common stock options, shares	1,172			1,172
Common stock issued for the exercise of warrants	$ 3,556,391			$ 121			3,556,270
Common stock issued for the exercise of warrants, shares				1,205,556
Restricted stock vested				$ 6			(6)
Restricted stock vested, shares	22,819			61,011
Stock-based compensation	$ 814,666						814,666
Net loss	(10,316,739)				(10,316,739)
Ending balance at Dec. 31, 2018	$ 6,425,885			$ 1,245	$ (45,289,526)	$ (6,464)	$ 51,720,630
Ending balance, shares at Dec. 31, 2018				12,449,379		808

Statements of Changes in Rede_2

Statements of Changes in Redeemable and Convertible Preferred Stock and Stockholders' (Deficiency) Equity (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Offering cost from private placement		$ 2,500
Net withheld for employee taxes	22,819
IPO [Member]
Offering cost from sale of stock		1,061,157
Over-allotment Option [Member]
Offering cost from sale of stock		$ 1,115,294

Statements of Cash Flows

Statements of Cash Flows - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Statement Of Cash Flows [Abstract]
Net loss		$ (10,316,739)	$ (12,097,479)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation		69,682	11,415
Stock-based compensation		814,666	279,508
Bad debt expense		16,275
Amortization of debt discount			17,765
Debt discount on convertible notes			5,172,000
Inventory reserve		32,645	42,355
Common stock issued for services and software license			31,845
Change in fair value of derivative liabilities		(36,269)	(116,795)
Changes in operating assets and liabilities:
Accounts receivable		(101,494)	(182,533)
Inventories		(140,817)	(161,075)
Prepaid expenses and other		(307,001)	(235,938)
Accounts payable and other accrued expenses		466,191	563,225
Accrued interest			377,503
Deferred revenue		(103,340)	38,067
Customer advance payments		(109)	106,718
Net cash used in operating activities		(9,606,310)	(6,153,419)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment		(126,867)	(67,002)
Net cash used in investing activities		(126,867)	(67,002)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments of issuance costs		(144,582)
Net settlement of vested restricted stock units to fund related employee statutory tax withholding		(74,213)
Proceeds from exercise of stock options		2	26,954
Proceeds from exercise of warrants		3,556,391	102,660
Proceeds from IPO, net of offering costs	[1]		4,368,315
Proceeds from private placement, net of offering costs			2,922,885
Proceeds from FPO, net of offering costs			10,407,706
Proceeds from convertible promissory notes, net			1,770,000
Repayment of note payable, MLSC			(1,215,900)
Net cash provided by financing activities		3,337,598	18,382,620
Net increase (decrease) in cash, cash equivalents, and restricted cash		(6,395,579)	12,162,199
Cash, cash equivalents, and restricted cash beginning of year		13,011,373	849,174
Cash, cash equivalents, and restricted cash end of year		6,615,794	13,011,373
SUPPLEMENTAL DISCLOSURE CASH FLOW INFORMATION
Cash paid during the period for interest			97,099
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventory capitalized as sales demo equipment		$ 53,178
Conversion of accrued interest to principal			21,916
Exchange of 2015 convertible promissory notes for 2016 convertible promissory notes			430,000
Accretion of convertible preferred stock to redemption value			274,011
Conversion of convertible preferred stock into common stock			12,946,252
Conversion of convertible promissory notes and accrued interest into common stock			5,467,389
Issuance of selling agent warrants in connection with IPO			156,725
Deferred offering costs to additional paid-in capital upon IPO closing	[1]		438,237
Common stock issued for repayment of promissory notes and related accrued interest			$ 1,217,172
[1]	IPO gross proceeds of $4,991,236 are reduced by $622,921 of IPO offering costs that were incurred in 2017. Another $438,237 of IPO deferred offering costs were paid for in 2016.

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statement Of Cash Flows [Abstract]
IPO gross proceeds	$ 4,991,236
IPO offering costs	$ 622,921
IPO deferred offering costs		$ 438,237

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	Note 1 — Description of Business Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company sells the product to orthotics and prosthetics (O&P) providers, the Veterans Health Administration (VA), rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, utilizing the clinical services of O&P providers for which they are paid a fee. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Cambridge, Massachusetts. Initial Public Offering under Regulation A and Private Placement under Regulation D On June 9, 2017, the Company completed its initial public offering (“IPO”) under Regulation A of the Securities Act of 1933, as amended, raising $4,991,235, before selling agent and other offering expenses of $1,061,157, through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. On June 9, 2017, concurrent with the closing of the IPO, the Company also closed on a private placement under Regulation D Rule 506(b) pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consisted of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share. The combined aggregate gross proceeds raised were $7,916,620. In connection with the closing of the Company’s IPO on June 9, 2017, the Company filed an amended and restated certificate of incorporation and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on October 23, 2016. Pursuant to the amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001. Follow-on Public Offering On December 4, 2017, the Company completed a follow-on public offering (“FPO”) in which the Company sold 4,175,000 shares of its common stock and 4,175,000 warrants to purchase shares of its common stock, at a price to the public of $2.40. The warrants, of which warrants to purchase 3,560,894 shares of common stock were outstanding as of December 31, 2018, are exercisable at an exercise price of $2.95 per share of common stock, and they expire on December 4, 2022. See Note 14 – Subsequent Events. On December 6, 2017, the Company’s underwriters on the FPO exercised in full its option to purchase 626,250 shares of common stock and accompanying warrant at a combined price to the public of $2.40 per combination. After giving effect to the full exercise of the over-allotment, the Company sold an aggregate of 4,801,250 shares of common stock and accompanying warrants to purchase an aggregate of 4,801,250 shares of common stock, raising $11,523,000 before underwriting discounts and other offering expenses of $1,115,000.

Going Concern and Management's

Going Concern and Management's Plan	12 Months Ended
	Dec. 31, 2018
Going Concern And Managements Plan [Abstract]
Going Concern And Management's Plan	Note 2 — Going Concern and Management’s Plan The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company incurred a net loss of $10,316,739 and $12,097,479 during the years ended December 31, 2018 and 2017, respectively, and has an accumulated deficit of $45,289,526 and $34,972,787 at December 31, 2018 and 2017, respectively. Cash used in operating activities was $9,606,310 and $6,153,419 for the years ended December 31, 2018 and 2017, respectively. In February 2019, the Company completed a follow-on offering of its common stock, generating net proceeds of approximately $5.6 million. The Company does not expect that its existing cash and net proceeds from the offering will be sufficient to fund its operations for the twelve months. from the filing date of these financial statements. The ability of the Company to continue as a going concern is dependent upon achieving a profitable level of operations and the ability of the Company to obtain necessary financing to fund ongoing operations. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance of these financial statements. On July 2, 2018, the Company filed a Registration Statement on Form S-3 (the “Shelf”) with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, warrants and/or units or any combination thereof the Company (collectively, the “Securities”) having an aggregate price of up to $75 million, subject to the limitations of the Shelf. The Company simultaneously entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as sales agent, to provide for the offering, issuance and sale by the Company of up to an aggregate amount of $15 million of the Company’s common stock from time to time in “at-the-market” offerings under the Shelf and subject to the limitations thereof. The Company shall pay to the sales agent cash commissions of 3.0% of the gross proceeds of sales of common stock under the Sales Agreement. Management plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern are primarily focused on raising additional capital in order to meet its obligations and execute its business plan by pursuing its product development initiatives and penetrate markets for the sale of its products. Management believes that the Company has access to capital resources through possible public or private equity offerings, including sales of common stock under the Sales Agreement, exercises of outstanding warrants, debt financings, or other means; however, the Company cannot provide any assurance that it will be able to raise additional capital or obtain new financing on commercially acceptable terms. If the Company is unable to secure additional capital, it may be required to curtail its operations or delay the execution of its business plan. There can be no assurance the Company will be successful in implementing its plans to alleviate substantial doubt.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving inventory. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at December 31, 2018 and 2017. Restricted cash consists of cash deposited with a financial institution as collateral for Company employee credit cards. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the balance sheets that sum to the total of the same amounts show in the statement of cash flows. 2018 2017 Cash and cash equivalents $ 6,540,794 $ 12,959,373 Restricted cash 75,000 52,000 Total cash, cash equivalents, and restricted cash in the balance sheet $ 6,615,794 $ 13,011,373 Accounts Receivable and Allowance for Doubtful Accounts The Company reports accounts receivable at invoiced amounts less an allowance for doubtful accounts. The Company evaluates its accounts receivable on a continuous basis, and if necessary, establishes an allowance for Inventories Inventories are recorded at the lower of cost or net realizable value. Cost is determined using a specific identification method. The Company reduces the carrying value of inventory for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors. In addition, the carrying value of consigned inventories is reduced by the value of MyPro devices that will not be sold based on historical experience. Restricted Cash Restricted cash consisted of cash deposited with a financial institution as collateral for Company credit cards for sales personnel. Deferred Offering Costs Deferred offering costs are comprised of direct incremental legal, accounting and financial advisor fees related relating to capital raising efforts. Deferred offering costs are offset against proceeds of an offering. In the event a capital raising effort is terminated, deferred offering costs are expensed. Equipment Equipment is stated at historical cost, net of accumulated depreciation and is depreciated using the straight-line method over the estimated useful lives of the related assets, generally three years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life, are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized. Demonstration units are sometimes provided to the Company’s indirect sales channel by the Company for marketing and patient evaluation purposes. These units are manufactured by the Company and are expensed in the statements of operations to selling, general, and administrative expense. During the years ended December 31, 2018 and 2017, respectively, the Company charged to operations approximately $256,700 and $26,900, respectively, of these units. Demonstrations units provided by the Company on its own sales force are capitalized as equipment on the Company’s balance sheet. Test units represent units provided to research and development staff to use in their development process and to end users who are given free units to act as testers so that research and development staff can evaluate and understand their use by patients. A primary objective of these units is to determine when and under what conditions they fail, at which time they are analyzed for cause of failure and then scrapped. These units are recorded at cost in the statements of operations as part of research and development expense. During the year ended December 31, 2018 and 2017 the Company charged to operations approximately $17,700 and $29,200, respectively, of these units. Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, including equipment when there are indications that the assets might be impaired. When evaluating assets for potential impairment, the Company compares the carrying value of the asset to its estimated undiscounted future cash flows. If an asset’s carrying value exceeds such estimated cash flows (undiscounted and with interest charges), the Company records an impairment charge for the difference. Based on its assessments, the Company did not record any impairment charges for the years ended December 31, 2018 and 2017. Accounts Payable and Other Accrued Expenses: 2018 2017 Trade payables $ 426,727 $ 264,890 Accrued compensation and benefits 1,027,757 642,425 Accrued directors fees — 100,000 Other 288,943 269,921 $ 1,743,427 $ 1,277,236 Derivative Liabilities The Company accounts for warrants determined to be derivative financial instruments by recording the warrants as a liability at fair value and marks-to-market the instruments at fair values as of each subsequent balance sheet date. Any change in fair value is recorded as a change in the fair value of derivative liabilities for each reporting period at each balance sheet date. The Company reassesses the classification at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As of December 31, 2018 and 2017, the Company’s only derivative liabilities are warrants issued to the selling agent for its IPO in 2017. Revenue Recognition The Company derives revenue primarily from the sale of its products to O&P providers, the VA, rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, utilizing the clinical services of O&P providers for which they are paid a fee. The Company recognizes revenue upon shipment, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance, the sales price is fixed or The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of certain new or revised financial accounting standards until they would apply to private companies. As such, we have delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. The Company receives federally-funded grants that require the Company to perform research activities as specified in each respective grant. The Company is paid based on the fees stipulated in the respective grants which approximate the projected costs to be incurred by the Company to perform such activities. The Company’s grant revenue is recognized when persuasive evidence of the arrangement exists, the service has been provided and adherence to specific parameters of the awarded grant have been met, the amount is fixed and determinable and collection is reasonable assured. The Company recognized approximately $64,600 and $118,100, respectively, of grant income in 2018 and 2017, respectively. Direct costs related to these grants are reported as a component of research and development costs in the statements of operations except for reimbursable costs which are reported as a component of cost of revenue in the statements of operations. Cost of revenue includes reimbursable costs of approximately $31,600 and $11,600 in 2018 and 2017, respectively. Amounts received in advance are deferred. Shipping and Handling Costs Shipping and handling costs paid by customers are netted against the related shipping costs we incur. The net cost is recorded in cost of sales. Historically, such costs have not been material. Income Taxes The Company accounts for income taxes under Accounting Standards Codification ASC 740 Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. ASC 740 requires that the tax effects of changes in tax laws or rates be recognized in the financial statement in the period in which the law is enacted. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company’s financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company’s financial condition, results of operations or cash flows. The Company files income tax returns in federal and state jurisdictions and is no longer subject to examinations by tax authorities for years prior to 2015. Currently, there are no income tax audits in process. Stock-Based Compensation The Company accounts for stock awards to employees by measuring the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. Options and warrants granted to consultants and other non-employees are recorded at fair value as of the grant date and subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Stock-based compensation expense of approximately $814,700 and $279,500 was recorded in research and development, selling, general and administrative expense in 2018 and 2017, respectively. Net Loss per Share Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Convertible debt, preferred stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the years ended December 31, 2018 and 2017, respectively, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potentially common shares issuable at December 31, 2018 and 2017 consist of: 2018 2017 Options 723,744 369,004 Warrants 5,071,887 6,277,443 Restricted stock units 38,125 — Restricted stock 38,269 — Total 5,872,025 6,646,447 Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $136,300 and $31,000 in 2018 and 2017, respectively. Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs primarily consist of salaries and benefits, facility and overhead costs, and outsourced research activities. Reclassification Certain prior period amounts included in the statement of cash flows for the year ended December 31, 2017 have been reclassified to conform to the current year’s presentation in accordance with ASU 2017-18. See “Recent Accounting Pronouncements.” Subsequent Events The Company evaluates events and/or transactions occurring after the balance sheet date and before the issue date of the financial statements to determine if any of those events and/or transactions require adjustment to or disclosure in the financial statements. Recent Accounting Pronouncements Revenue Related Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers: Topic 606,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 — Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers—Principal versus Agent Considerations.” This update provides clarifying guidance regarding the application of ASU No. 2014-09 — Revenue from Contracts with Customers when another party, along with the reporting entity, is involved in providing a good or a service to a customer. In these circumstances, an entity is required to determine whether the nature of its promise is to provide that good or service to the customer (that is, the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (that is, the entity is an agent). The amendments in the Update clarify the implementation guidance on principal versus agent considerations. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2016-12”). ASU 2016-12 provides clarifying guidance in a few narrow areas and adds some practical expedients to the guidance. In September 2017, the FASB issued ASU No. 2017-13, “Revenue Recognition (Topic 605) and Revenue from Contracts with Customers (Topic 606). The Company qualifies as an “emerging growth company” as defined in the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of certain new or revised financial accounting standards until they would apply to private companies. As such, the Company delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). The Company is adopting ASU No 2016-08 and related ASC 606 amendments effective January 1, 2019 using the modified retrospective method. Based on the results of the Company’s assessment to date, this standard did not have a material impact on the Company’s financial statements for 2018 and is not expected to have a material impact in future years. The Company will enhance its revenue recognition disclosures, as required by this standard, including significant judgments and practical expedients used by the Company in applying the five-step revenue model. The cumulative impact to the Company’s accumulated deficit as of December 31, 2018 is expected to be de minimums. Other Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. As an emerging growth company, the Company expects to delay adoption of ASU 2016-02 until January 1, 2020. ASU 2016-02 is not expected to have a material impact on the financial statements or disclosures. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This update simplifies several aspects of the accounting for share-based payment awards, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2017, including interim periods. The Company adopted this standard effective January 1, 2018, using a modified retrospective transition approach, which requires that the cumulative effect of initially applying the standard to be recorded as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application. We elected to no longer calculate an estimate of expected forfeitures and began recognizing forfeitures as they occur. The cumulative-effect adjustment to accumulated deficit at January 1, 2018 was immaterial. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,” which addresses the diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows with respect to eight specific cash flow issues. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The amendments should be applied using a retrospective transition method to each In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)”, which clarifies how entities should present restricted cash and restricted cash equivalents in the statement of cash flows, and as a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. An entity with a material balance of restricted cash and restricted cash equivalents must disclose information about the nature of the restrictions. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted and the new guidance must be applied retroactively to all periods presented. The adoption of this standard did not have a material impact to the financial statements or disclosures. In May 2017, the FASB issued ASU No. 2017-09, Compensation — Stock Compensation (Topic 718); Scope of Modification Accounting. The amendments in this ASU provide guidance that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. If the value, vesting conditions or classification of the award changes, modification accounting will apply. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of this standard did not have a material impact to the financial statements or disclosures. In July 2017, the FASB issued ASU No. 2017-11, which changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU No. 2017-11 also clarifies existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. ASU No. 2017-11 requires entities to recognize the effect of the down round feature in a freestanding equity-classified financial instrument only when it is triggered. The effect of triggering such a feature will be recognized as a dividend and a reduction to income available to common shareholders in basic. ASU No. 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts ASU No. 2017-11 in an interim period, adjustments should be reflected as of the beginning of the interim period in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which ASU No. 2017-11 is effective or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. During the fourth quarter of 2017, we early adopted ASU No. 2017-11. The early adoption of ASU 2017-11 resulted in the warrants issued in conjunction with our December 2017 FPO, which contain the aforementioned down-round feature, being accounted for as an equity instrument rather than a derivative liability. In June 2018, the FASB issued ASU No. 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company is currently evaluating the accounting, transition, and disclosure requirements of the standard to determine the impact, if any, on its financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” The ASU requires application of the prospective method of transition (for only the most recent interim or annual period presented in the initial fiscal year of adoption) to the new disclosure requirements for (1) changes in unrealized gains and losses included in OCI and (2) the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU also requires prospective application to any modifications to disclosures made because of the change to the requirements for the narrative description of measurement uncertainty. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. The Company is currently evaluating the accounting, transition, and disclosure requirements of the standard to determine the impact, if any, on its financial statements. Subsequent Events The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed herein, there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventories	Note 4 — Inventories Inventories consist of the following at December 31: 2018 2017 Finished goods $ 146,640 $ 122,000 Consigned inventory 135,635 97,980 Parts and components 48,874 23,530 331,149 243,510 Less: excess and obsolete inventory reserves (24,000 ) (23,739 ) Less: consigned inventory reserves (51,000 ) (18,616 ) Inventories, net $ 256,149 $ 201,155 Consigned inventory represents products that have been delivered for which the Company does not have the right to bill. At December 31, 2018 and 2017, the Company has recorded reserves for excess and obsolete inventory and consigned inventory for units that will not sold based on historical experience.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Equipment	Note 5 — Equipment Equipment consists of the following at December 31: 2018 2017 Computer equipment $ 76,424 $ 32,257 Sales demonstration units 155,293 54,003 R&D tools and molds 52,644 22,650 Furniture and fixtures 3,270 — 287,631 108,910 Less: accumulated depreciation (100,118 ) (31,760 ) Equipment, net $ 187,513 $ 77,150

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 6 — Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: • Level 1 — Quoted prices available in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs. The carrying amounts of the Company’s financial instruments such as cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents are a money market fund that limits its investments to only short-term U.S. Treasury securities and repurchase agreements related to these securities. Cash equivalents and derivative liabilities (see Note 10) measured at fair value on a recurring basis at December 31, 2018 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2018 Total Cash equivalents $ 6,037,456 — — $ 6,037,456 Common stock warrant liabilities — — $ 3,661 $ 3,661 Cash equivalents and derivative liabilities (see Note 10) measured at fair value on a recurring basis at December 31, 2017 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2017 Total Cash equivalents $ 10,459,435 — — $ 10,459,435 Common stock warrant liabilities — — $ 39,930 $ 39,930 The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the year ended December 31, 2018 and 2017: Common stock warrant liability Balance – January 1, 2017 $ — Fair value of common stock warrant issued 156,725 Change in fair value of derivative liabilities (116,795 ) Balance – December 31, 2017 39,930 Change in fair value of derivative liabilities (36,269 ) Balance – December 31, 2018 $ 3,661 Assumptions utilized in the valuation of Level 3 liabilities at December 31, were as follows: 2018 2017 Risk-free interest rate 2.51% 2.20% Expected life 3.44 years 4.44 years Expected volatility of underlying stock 62% 63% Expected dividend yield — — The expected stock price volatility for the Company’s common stock warrant liabilities was determined by the historical volatilities for industry peers and used an average of those volatilities. Risk free interest rates were obtained from U.S. Treasury rates for the applicable periods. The expected term used is the contractual life of the instrument being valued. The expected dividend yield was not considered in the valuation of the common stock liabilities as the Company has never paid, nor has the intention to pay, cash dividends.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Common Stock	Note 7 — Common Stock On July 2, 2018, the Company filed a Registration Statement on Form S-3 (the “Shelf”) with the Securities and Exchange Commission in relation to the registration of common stock, preferred stock, warrants and/or units or any combination thereof the Company (collectively, the “Securities”) having an aggregate price of up to $75 million, subject to the limitations of the Shelf. The Company simultaneously entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc., as sales agent, to provide for the offering, issuance and sale by the Company of up to an aggregate amount of $15 million of the Company’s common stock from time to time in “at-the-market” offerings under the Shelf and subject to the limitations thereof. The Company shall pay to the sales agent cash commissions of 3.0% of the gross proceeds of sales of common stock under the Sales Agreement. As of the filing date of these financial statements, the Company has not sold any common stock under the Sales Agreement. On June 9, 2017, the Company completed its IPO raising $4,991,235, before selling agent commissions and other offering expenses of $1,061,157, through the sale of 665,498 shares of its common stock at a price of $7.50 per share. On June 9, 2017, the Company concurrently closed on a private placement pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share. Upon the closing of the Company’s IPO on June 9, 2017, in accordance with the terms of the 2016 convertible promissory notes, the principal balance of these notes, and all accrued but unpaid interest, totaling $5,467,389 were converted into 1,055,430 shares of common stock at weighted-average price of $5.18 per share. In connection with the closing of the Company’s IPO on June 9, 2017, the Company filed an amended and restated certificate of incorporation and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on October 23, 2016. Pursuant to the amended and restated certificate of incorporation, the Company is authorized to issue up to 125,000,000 shares of stock, consisting of 100,000,000 shares of common stock, par value $0.0001 and 25,000,000 shares of undesignated Preferred Stock, par value of $0.0001. On December 4, 2017, the Company completed a follow-on public offering (“FPO”) in which the Company sold 4,175,000 shares of its common stock and 4,175,000 warrants to purchase shares of its common stock, at a price to the public of $2.40. The warrants, of which warrants to purchase 3,560,894 shares of common stock remain outstanding as of December 31, 2018, are exercisable at an exercise price of $2.95 per share of common stock, and they expire on December 4, 2022. See Note 14 – Subsequent Events. On December 6, 2017, the Company’s underwriters on the FPO exercised in full its option to purchase 626,250 shares of common stock and accompanying warrant, at a combined price to the public of $2.40 per combination. After giving effect to the full exercise of the over-allotment, the Company sold an aggregate of 4,801,250 shares of common stock and accompanying warrants to purchase an aggregate of 4,801,250 shares of common stock, raising $11,523,000 before underwriting discounts and other offering expenses of $1,115,000. Subsequent to the FPO, an aggregate of 1,205,556 and 34,800 of these warrants were exercised during the years ended December 31, 2018 and 2017, respectively, for additional gross proceeds of $3,556,000 and $102,660 during the years ended December 31, 2018 and 2017, respectively. On November 13, 2017, the Company repaid all outstanding principal and accrued but unpaid interest under certain notes payable, totaling approximately $1,081,135 in cash by issuing 107,505 shares of the Company’s common stock at a price per share equal to $5.03, 80% of the price per share of common stock on the repayment date, and issuing 86,004 shares of the Company’s common stock at a price per share equal to $6.29, the price per share of common stock on the repayment date. In June 2017, the Company issued 4,000 shares to an investor relations firm for services performed. The Company recorded a charge to operations for $30,000 for the fair value of the stock issued. During the year ended December 31, 2018 and 2017, the Company issued 1,172 and 80,085 shares of common stock through the exercise of stock options for proceeds of $2 and $26,954, respectively. During the year ended December 31, 2018, the Company issued 42,781 During the year ended December 31, 2018 and 2017, the Company issued 61,011 and 312 shares of common stock upon the vesting of restricted stock awards, respectively.

Treasury Stock

Treasury Stock	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Treasury Stock	Note 8 — Treasury Stock Treasury stock is reported at cost and consists of 808 shares of common stock as of December 31, 2018 and 2017.

Stock Award Plans and Stock-bas

Stock Award Plans and Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Award Plans and Stock-based Compensation	Note 9 — Stock Award Plans and Stock-based Compensation Equity Incentive Plan On June 19, 2018, the Company’s Shareholders and the Board of Directors approved the Myomo, Inc. 2018 Stock Options and Incentive Plan (the “2018 Plan”). The number of shares of common stock available for awards under the 2018 Plan was equal to 706,119 shares which carried over the remaining 86,119 shares available for grant under the 2016 Plan on April 1, 2018 and an increase of the share reserve by 620,000 shares. On January 1, 2019 and each January thereafter, the number of shares of common stock reserved and available for issuance under the 2018 Plan will cumulatively increase by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee. At December 31, 2018, there were 505,153 shares available for future grant under the 2018 Plan. On October 25, 2016, the Company’s shareholders approved the 2016 Equity Incentive Plan (2016 Plan) which became effective on June 9, 2017, the date that the Company completed its IPO. Upon effectiveness of the 2016 Plan, no additional awards have been granted under the Company’s prior equity incentive plans. The Company reserved 562,500 shares of its Common Stock for issuance under the 2016 Plan. Participation in the 2016 Plan will continue until all of the benefits to which the participants are entitled have been paid in full. Under the terms of the Stock Plans, incentive stock options (ISOs) may be granted to officers and employees and non-qualified stock options and awards may be granted to directors, consultants, officers and employees of the Company. The exercise price of ISOs cannot be less than the fair market value of the Company’s Common Stock on the date of grant. The options vest over a period determined by the Company’s Board of Directors, ranging from immediate to four years, and expire not more than ten years from the date of grant. Stock Option Awards Stock option activity under the Stock Option Plans during the years ended December 31, 2018 and 2017 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Life (years) Intrinsic Value Balance at January 1, 2017 246,344 $ 0.5133 7.10 $ 132,121 Granted 210,600 2.6568 Forfeited or cancelled (7,855 ) 0.9717 Exercised (80,085 ) 0.3366 Balance at December 31, 2017 369,004 1.7652 8.65 $ 732,399 Granted 375,186 3.0700 Forfeited or cancelled (13,632 ) 3.1100 Expired (5,642 ) 1.6900 Exercised (1,172 ) 3.8700 Balance at December 31, 2018 723,744 $ 2.4200 8.51 $ 157,260 Options exercisable at December 31, 2017 141,847 $ 0.6906 5.68 $ 99,879 Options exercisable at December 31, 2018 336,718 $ 1.9500 7.74 $ 141,506 The Company uses the Black-Scholes option pricing model to estimate the grant date fair value of its stock options. There was no income tax benefit recognized in the financial statements for share-based compensation arrangements for the years ended December 31, 2018 and 2017. The weighted-average grant date fair value per share was $1.77 and $1.62 for the years ended December 31, 2018 and 2017, respectively. The assumptions underlying the calculation of grant date fair value are as follows: 2018 2017 Volatility 60.00%-61.96% 62.71%-80.00% Risk-free interest rate 2.65%-3.17% 0.58%-2.29% Weighted-average expected option term (in years) 6.25-9.92 5.75-6.25 Dividend yield 0% 0% The stock price volatility for the Company’s options was determined using historical volatilities for industry peers. The risk free interest rate was derived from U.S. Treasury rates existing on the date of grant for the applicable expected option term. The expected term represents the period of time that options are expected to be outstanding. Because the Company has only very limited historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. The expected dividend yield assumption is based on the fact that the Company has never paid, nor has any intention to pay, cash dividends. Restricted Stock Awards Restricted stock activity for the years ended December 31, 2018 and 2017 is summarized below: Number of Shares Weighted average grant date fair value Weighted average remaining contractual life (in years) Outstanding as January 1, 2017 — $ — — Awarded 46,500 6.75 Vested (312 ) 6.75 Canceled (2,000 ) 6.75 Outstanding as December 31, 2017 44,188 6.75 6.75 Awarded 55,092 3.27 Vested (61,011 ) 4.83 Canceled — — Outstanding as of December 31, 2018 38,269 $ 4.80 1.39 On August 15, 2017, the Company granted 46,500 restricted stock awards to certain executives and other managers at an aggregate fair market value on the date of grant of $313,900. The restricted stock awards vest over a period determined by the Company’s Board of Directors, ranging from five months to four years. The Company recorded $123,000 in compensation expense during the year ended December 31, 2017 in connection with the grant of these restricted stock awards. On January 3, 2018, the Company issued 15,228 shares of common stock to members of the Company’s board of directors. The shares of stock were fully vested on the date of issuance and the Company recorded a charge to operations for the fair value of shares in the amount of $60,000. On June 19, 2018, the Company issued 39,864 shares of common stock to members of the Company’s board of directors. The Company determined the fair value of the units based on the closing price of the Company’s common stock on the grant date. The compensation expense is being amortized over the respective vesting periods. The restricted stock units become fully vested on June 30, 2019. Restricted Stock Units Restricted stock unit activity for the year ended December 31, 2018 is summarized below: Number of Shares Weighted average grant date fair value Weighted average remaining contractual life (in years) Outstanding as of January 1, 2018 — — — Awarded 103,723 3.56 Vested (65,598 ) 3.68 Canceled — 3.35 Outstanding as of December 31, 2018 38,125 3.35 1.49 On January 2, 2018, the Company granted 88,723 restricted stock units to key employees. They were issued with lapsing forfeiture rights extending up to 24 months. At December 31, 2018, 23,123 restricted stock units were subject to forfeiture. The Company determined the fair value of the units based on the closing price of the Company’s common stock on the grant date. The compensation expense is being amortized over the respective vesting periods. The Company recorded a charge in the amount of $242,551 for the year ended December 31, 2018. On July 9, 2018, the Company granted 5,000 restricted stock units to an officer of the Company which vest in full on the first anniversary date. The Company also issued 10,000 restricted stock units to the same officer which vest over four years. Awards of restricted stock units are generally net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. These payments of employee withholding taxes are presented are presented in the statements of cash flows as a financing activity. Share-Based Compensation Expense The Company attributes the value of stock-based compensation, net of estimated forfeitures, to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period. The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and restricted stock awards to employees and directors, and restricted stock units to employees in the statements of operations as follow: 2018 2017 Research and development $ 103,457 $ 12,382 Selling, general and administrative 711,209 267,126 Total $ 814,666 $ 279,508 As of December 31, 2018, there was approximately $586,600 of unrecognized compensation cost related to unvested stock options and is expected to recognized over a weighted-average period of 2.16years. As of December 31, 2018, there was approximately $164,300 of total unrecognized compensation cost related to unvested restricted stock awards and is expected to recognized over a weighted-average period of 1.39 years. As of December 31, 2018, there was approximately $ 116,800 of unrecognized compensation cost related to unvested restricted stock unit awards and is expected to recognized over a weighted-average period of 1.49 years.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Warrants And Rights Note Disclosure [Abstract]
Warrants	Note 10 — Warrants On June 9, 2017, the Company issued warrants for the purchase of 557,216 shares of common stock to investors in connection with a private placement that closed concurrently with the Company’s IPO, as more fully described in Note 1. The warrants are exercisable for three years from the date of the IPO and are fully vested and exercisable at any time by the holder at a price of $7.50 per share. The warrants can only be settled in the Company’s own shares, and as such, under ASC 815 “Derivatives and Hedging” the warrants were deemed to be equity instruments and, therefore are included in stockholders’ equity and no fair value adjustments are required from period-to-period. On June 9, 2017, the Company issued warrants for the purchase of 33,275 shares of common stock to its IPO selling agent. The warrants are fully vested, exercisable at any time after December 9, 2017 by the holder at an exercise price of $8.25 per share and have a life of five years. The warrants include a fundamental transaction clause which provides for the warrant holder to be paid in cash upon an event as defined in the warrant. The cash payment is to be computed using the Black-Scholes valuation model for the unexercised portion of the warrant. Accordingly, under ASC 815 Derivatives and Hedging the warrants were deemed to be a derivative liability and are marked to market at each reporting period. Accordingly, on the date of issuance the Company recorded as a derivative liability the fair value of the warrants which was $156,725 and at December 31, 2017 the derivative liability was marked to its then fair market value of $39,930. On December 4, 2017, the Company issued 4,175,000 warrants to purchase shares of its common stock to investors in connection with its FPO, as more fully described in Note 1. The warrants, of which warrants to purchase 3,560,894 shares of common stock remain outstanding as of December 31, 2018, are exercisable at an exercise price of $2.95 per share of common stock, and they expire on December 4, 2022. The exercise price of these warrants has been subsequently reduced to $1.40 per share (see Note 14 – Subsequent Events). On December 6, 2017, the Company’s underwriters on its FPO exercised in full their option to purchase 626,250 shares of common stock and accompanying warrant. After giving effect to the full exercise of the over-allotment, the Company issued an aggregate 4,801,250 warrants to purchase an aggregate of 4,801,250 shares of common stock at an exercise price of $2.95 per share of common stock, which expire on December 4, 2022. The early adoption of ASU 2017-11 by the Company, during the fourth quarter of 2017, resulted in the warrants issued in conjunction with the December 2017 FPO, which contain a “down-round” feature, being accounted for as an equity instrument rather than a derivative liability. Down round features are features of certain equity-linked instruments (or embedded features) that may result in the strike price being reduced on the basis of the pricing of future equity offerings. Upon adoption of ASU 2017-11, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The warrants can only be settled in the Company’s own shares, and as such, under ASC 815 Derivatives and Hedging, they were deemed to be equity instruments and, therefore are included in stockholders’ equity and no fair value adjustments are required from period-to-period. On December 4, 2017, the Company issued warrants for the purchase of 83,500 shares of common stock to the underwriter of its FPO. The warrants are fully vested, exercisable at any time after June 2, 2018 by the holder at an exercise price of $2.40 per share and have a life of three years. The warrants can only be settled in the Company’s own shares, and as such, under ASC 815 Derivatives and Hedging, they were deemed to be equity instruments and, therefore are included in stockholders’ equity and no fair value adjustments are required from period-to-period. The following table presents the Company’s common stock warrant activity for the years ended December 31, 2018 and 2017: Warrants Weighted Average Exercise Price Outstanding Exercisable Outstanding Exercisable Balance, Jan 1, 2017 8,228 8,228 $ 6.47 $ 6.47 Issued 6,304,015 6,220,515 3.84 3.85 Exercised (34,800 ) (34,800 ) 2.95 2.95 Balance, Dec 31, 2017 6,277,443 6,193,943 3.85 3.86 Previously issued warrants which became exerciseable — 83,500 2.40 2.40 Issued — — — — Exercised (1,205,556 ) (1,205,556 ) 2.95 2.95 Balance, Dec 31, 2018 5,071,887 5,071,887 $ 4.05 $ 4.05 The weighted average remaining contractual life of warrants outstanding and exercisable at December 31, 2018 was 3.23 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 — Related Party Transactions The Company sells its products to an orthotics and prosthetics practice whose ownership includes an individual who is both a minority shareholder and employee of the Company. Sales to this related party are sold at standard list prices. During the years ended December 31, 2018 and 2017 revenue recognized on sales to this orthotics and prosthetics practice amounted to approximately $306,200 and $53,500, respectively. There were no amounts due for this related party as of December 31, 2018. Included in accounts receivable at December 31, 2017 is approximately and $77,600, respectively, and due to the related party. The Company also obtains consulting and fabrication services from the same related party. Charges for these services amounted to approximately $530,300 and $356,400 during the years ended December 31, 2018 and 2017, respectively. Included in accounts payable and accrued expenses at December 31, 2018 and 2017 is approximately $54,300 and $65,800, respectively, due to the related party. An officer and director purchased 14,000 shares at $7.50 per share in the Company’s June 9, 2017 IPO. Certain directors and officers of the Company purchased 125,238 shares and 125,238 warrants to purchase shares of common stock, in the Company’s private placement under Regulation D Rule 506(b) that closed concurrently with its IPO on June 9, 2017, at the price of $5.25 per unit. The warrants are exercisable at an exercise price of $7.50 per share of common stock. Certain directors and officers of the Company purchased 285,000 shares and 285,000 warrants to purchase shares of its common stock in the Company’s FBO, that closed on December 4, 2017, at the price to the public of $2.40. The warrants are exercisable at an exercise price of $2.95 per share of common stock.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12 — Commitments and Contingencies Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Currently, there is no litigation against the Company. Operating Leases The Company has a month-to-month lease agreement for office space. Rent expense for the years ended December 31, 2018 and 2017 was approximately $352,800 and $221,200, respectively. Licensing Agreement During 2006, the Company entered into an exclusive licensing agreement for access to certain patent rights that require the payment of royalties, which vary based on the level of the Company’s net sales. As part of the agreement, the Company must pay a nonrefundable annual license maintenance fee which may be credited to any royalty amounts due in that same year. The license agreement can be terminated if certain sales targets are not achieved. The royalty charge for each of the years ended December 31, 2018 and 2017 was $49,300 and $25,000, respectively, and is included as a component of cost of sales. The future minimum amounts due under this agreement for the next five years are as follows: 2019 $ 25,000 2020 25,000 2021 25,000 2022 25,000 2023 (year patents expire) 25,000 Under the licensing agreement, the Company has issued 6,172 shares of Common Stock to MIT, including 492 shares on December 29, 2017, pursuant to a licensing agreement share adjustment provision in the event that the Company has a dilutive financing, as defined. The licensing agreement also includes an anti-dilution provision such that the licensor’s ownership of the outstanding Common Stock shall not fall below 1% on a fully diluted basis. Such issuances of Common Stock continue until the date upon which the Company received a total of $3,000,000 for its capital stock. After the date the funding threshold was met in 2007, the licensor has the right to purchase additional shares of common stock to maintain its pro rata ownership. On November 15, 2016, the Company and MIT entered into a waiver agreement with regard to certain revenue and commercialization milestones of the Company required under the License Agreement. Under the waiver agreement, MIT waived the compliance with any and all of such milestone obligations prior to the date of the waiver agreement. For the year ended December 31, 2018 the Company met its minimum sales covenant of $750,000. Clinical Research Studies The Company had in-process contracts with various universities and a research hospital to conduct clinical research studies in 2018 to enhance the Company’s products, increase the body of evidence to support prescribing and reimbursing the Company’s devices, and to grow its range of product offerings. These contracts were completed in 2018. Warranty Liability The Company accrues an estimate of their exposure to warranty claims based on both current and historical product sales data and warranty costs incurred. The majority of the Company’s current products carry a three-year warranty, but prior to 2017 most products carried a one-year warranty. The Company assesses the adequacy of their recorded warranty liability annually and adjusts the amount as necessary. Changes in warranty liability were as follows: 2018 2017 Accrued warranty liability, beginning of year $ 50,725 $ 63,147 Accrual provided for warranties issued during the period 23,452 14,867 Adjustments to prior accruals 38,382 570 Actual warranty expenditures (20,559 ) (27,859 ) Accrued warranty liability, end of year $ 92,000 $ 50,725 Credit Risk Financial instruments that potentially expose the Company to a concentration of credit risk consist primarily of cash, cash equivalents and restricted cash and accounts receivable. The Company maintains its cash, cash equivalents and restricted cash, with balances in excess of federally insured limits, with major financial institutions that management believes are financially sound and have minimum credit risk. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant credit risks related to cash. Major Customers For the year ended December 31, 2018 two customers accounted for approximately 25% of revenues, excluding grant income which includes 13% from a related party. The Company sells its product to an orthotics and prosthetics practice whose ownership includes an individual who is both a minor shareholder and employee of the company. For the year ended December 31, 2017 three customers accounted for approximately 23%, 17%, and 14%, of revenues, excluding grant income. As of December 31, 2018, two customers accounted for approximately 20% and 16% of accounts receivable. As of December 31, 2017, three customers accounted for approximately 55% of accounts receivable, 26% of which was due from the aforementioned related party, 18% and 11%.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 — Income Taxes The income tax provision (benefit) for the years ended December 31, 2018 and 2017 consist of the following: 12/31/18 12/31/17 U.S. federal Current $ — $ — Deferred (2,065,000 ) (534,000 ) State and local Current — — Deferred (571,000 ) (538,000 ) (2,636,000 ) (1,072,000 ) Deferred tax expense related to tax law change — 2,909,000 Change in valuation allowance 2,636,000 (1,837,000 ) Income tax provision $ — $ — The reconciliation between the U.S statutory federal income tax rate and the Company’s effective rate for the years ended December 31, 2018 and 2017 is as follows: 12/31/18 12/31/17 U.S. federal statutory rate 21.00 % 34.00 % State income taxes, net of federal benefit 5.57 % 4.67 % Federal rate change, deferred items 0.00 % (23.03 )% State rate change and other (0.03 )% 0.89 % Non-deductible interest 0.00 % (17.67 )% Federal NOLs to expire unutilized due to sec 382 limitation 0.00 % (14.02 )% Other permanent items (0.98 )% (0.03 )% Change in valuation allowance (25.56 )% 15.19 % Effective rate 0.00 % 0.00 % As of December 31, 2018, and 2017, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: 12/31/18 12/31/17 Net operating loss carryover $ 8,378,000 $ 5,925,000 Tax credits 178,000 190,000 Stock-based compensation 27,000 53,000 Other 440,000 219,000 Total deferred tax asset 9,023,000 6,387,000 Less: valuation allowance (9,023,000 ) (6,387,000 ) Deferred tax asset, net of valuation allowance $ — $ — There were no deferred tax liabilities at December 31, 2018 or 2017. As of December 31, 2018 and 2017, the Company had approximately $35,519,000 and $26,425,000 of Federal net operating loss (“NOL”), and $29,212,000 and $22,046,000 of state NOLs, respectively, available to offset future taxable income. The Federal NOLs incurred prior to 2018 of $26,425,000, if not utilized, begin expiring in the year 2028. The Federal NOLs incurred in 2018 of $9,094,000 have an indefinite carryforward period. The state NOLs, if not utilized begin to expire in 2019 through 2027. During 2017, the Company experienced an ownership change within the meaning of Section 382 of the Internal Revenue Code of 1986. The ownership change has and will continue to subject the Company’s pre-ownership change net operating loss carryforwards to an annual limitation, which will significantly restrict its ability to use them to offset taxable income in periods following the ownership change. The annual use limitation equals the aggregate value of the Company’s stock at the time of the ownership change multiplied by a specified tax-exempt interest rate. Ownership changes were also determined to have occurred during the third quarter of 2014 and second quarter of 2015. As a result of these ownership changes, the Company is limited to an approximate $1,559,000 annual limitation on its ability to utilize pre-change NOLs during the carryforward period and has determined that approximately $5,000,000 of the Company’s pre-change NOLs will expire unutilized. Accordingly, the deferred tax asset and valuation allowance have been adjusted by approximately $1,700,000 to reflect the Federal NOLs that will expire unutilized. On December 22, 2017, the Tax Cuts and Jobs Act (TCIA) was signed into law. The enacted law reduces the corporate tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017. ASC 740 requires that the tax effects of changes in tax laws or rates be recognized in the period in which the law is enacted. As a result of the enacted law, the Company is required to revalue deferred tax assets and liabilities at the enacted rate and reflect that change in its financial statements for the period that includes the date of enactment, since the deferred tax items would be expected to reverse at the reduced rate. As a result of the corporate tax rate decrease from the Tax Cuts and Jobs Act (TCIA), the deferred tax assets and valuation allowance have been reduced by approximately $2,909,000 at December 31, 2017. ASC 740, “Income Taxes” requires that a valuation allowance be established when it is “more likely than not” that all, or a portion of, deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. After consideration of all the information available, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of December 31, 2018 and 2017. For the years ended December 31, 2018 and December 31, 2017, the change in valuation allowance was a decrease of $2,636,000 and an increase of $1,837,000, respectively. The Company recognizes interest and penalties relating to unrecognized tax benefits on the income tax expense line in the statement of operations. There are no tax penalties and interest on the statement of operations as of December 31, 2018, 2017 and 2016. The Company operates in multiple tax jurisdictions and, in the normal course of business, its tax returns are subject to examination by various taxing authorities. Such examinations may result in future assessments by these taxing authorities. The Company is subject to examination by U.S. tax authorities beginning with the year ended December 31, 2015. No accrued interest and penalties are included on the related tax liability accrual on the balance sheet. There are no accrued interest and penalties at December 31, 2018 and December 31, 2017.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 14 — Subsequent Events Underwritten Public Offering On February 12, 2019, the Company completed an underwritten public offering in which the Company sold 4,542,500 shares of its common stock at a price to the public of $1.40. All of the shares of common stock sold were offered by the Company and were pursuant to a prospectus dated July 16, 2018, and a preliminary prospectus supplement dated February 7, 2019, in connection with a takedown from the Company’s shelf registration statement on Form S-3 (Registration No. 333-226045) (as amended, the “Registration Statement”), which the U.S. Securities and Exchange Commission declared effective on July 16, 2018. The gross proceeds to the Company, before deducting the underwriting discount and estimated other offering expenses, were approximately $6.4 million. On February 12, 2019, the Company issued to the underwriter a warrant (the “Underwriter Warrant”) to purchase 363,400 shares of common stock. The Underwriter Warrant has an exercise price $1.75 per share and may be exercised on a cashless basis in certain circumstances specified in the Underwriter Warrant. The Underwriter Warrant is exercisable six months from the date of issuance and will expire four years from the date of issuance. The Underwriter Warrant provides for adjustment in the number and price of such Underwriter Warrant (and the shares of common stock underlying such Underwriter Warrant) in the event of a recapitalization, merger or other fundamental transaction. The Company issued warrants (the “2017 Warrants”) in its December 2017 public offering. Pursuant to the terms of the warrants, the sale and issuance in this underwritten public offering of Common Stock at a public offering price of $1.40 per share triggered an adjustment to the exercise price of the outstanding 2017 Warrants. The exercise price of such warrants was reduced from $2.95 per share to $1.40 per share, pursuant to the terms of such warrants. Stock Awards Grante d Subsequent to December 31, 2018, the Company issued: 156 shares of common stock issued upon vesting of restricted stock awards with an aggregate fair value of $1.63 at the time of vesting. 91,368 shares of common stock granted restricted stock units (RSUs) to key employees with an aggregate fair value of $1.60 at the grant date. On February 6, 2019, the Company announced the hiring of a Chief Financial Officer and pursuant to his employment agreement, the Company made the following grants for equity compensation to the Chief Financial Officer: • 50,000 Incentive Stock Options which vest 25% on the first anniversary of February 18, 2019 grant date and thereafter in 36 equal monthly installments, subject to continuous service with the Company; and • 20,000 Restricted Stock Units which vest 25% on the first anniversary of the February 18, 2019 grant date, and thereafter in 12 equal quarterly installments, subject to continuous service with the Company.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from those estimates. The Company’s significant estimates include the allowance for doubtful accounts, deferred tax valuation allowances, warranty obligations and reserves for slow-moving inventory.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at December 31, 2018 and 2017. Restricted cash consists of cash deposited with a financial institution as collateral for Company employee credit cards. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the balance sheets that sum to the total of the same amounts show in the statement of cash flows. 2018 2017 Cash and cash equivalents $ 6,540,794 $ 12,959,373 Restricted cash 75,000 52,000 Total cash, cash equivalents, and restricted cash in the balance sheet $ 6,615,794 $ 13,011,373
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts The Company reports accounts receivable at invoiced amounts less an allowance for doubtful accounts. The Company evaluates its accounts receivable on a continuous basis, and if necessary, establishes an allowance for
Inventories	Inventories Inventories are recorded at the lower of cost or net realizable value. Cost is determined using a specific identification method. The Company reduces the carrying value of inventory for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors. In addition, the carrying value of consigned inventories is reduced by the value of MyPro devices that will not be sold based on historical experience.
Restricted Cash	Restricted Cash Restricted cash consisted of cash deposited with a financial institution as collateral for Company credit cards for sales personnel.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are comprised of direct incremental legal, accounting and financial advisor fees related relating to capital raising efforts. Deferred offering costs are offset against proceeds of an offering. In the event a capital raising effort is terminated, deferred offering costs are expensed.
Equipment	Equipment Equipment is stated at historical cost, net of accumulated depreciation and is depreciated using the straight-line method over the estimated useful lives of the related assets, generally three years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life, are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized. Demonstration units are sometimes provided to the Company’s indirect sales channel by the Company for marketing and patient evaluation purposes. These units are manufactured by the Company and are expensed in the statements of operations to selling, general, and administrative expense. During the years ended December 31, 2018 and 2017, respectively, the Company charged to operations approximately $256,700 and $26,900, respectively, of these units. Demonstrations units provided by the Company on its own sales force are capitalized as equipment on the Company’s balance sheet. Test units represent units provided to research and development staff to use in their development process and to end users who are given free units to act as testers so that research and development staff can evaluate and understand their use by patients. A primary objective of these units is to determine when and under what conditions they fail, at which time they are analyzed for cause of failure and then scrapped. These units are recorded at cost in the statements of operations as part of research and development expense. During the year ended December 31, 2018 and 2017 the Company charged to operations approximately $17,700 and $29,200, respectively, of these units.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, including equipment when there are indications that the assets might be impaired. When evaluating assets for potential impairment, the Company compares the carrying value of the asset to its estimated undiscounted future cash flows. If an asset’s carrying value exceeds such estimated cash flows (undiscounted and with interest charges), the Company records an impairment charge for the difference. Based on its assessments, the Company did not record any impairment charges for the years ended December 31, 2018 and 2017. Accounts Payable and Other Accrued Expenses: 2018 2017 Trade payables $ 426,727 $ 264,890 Accrued compensation and benefits 1,027,757 642,425 Accrued directors fees — 100,000 Other 288,943 269,921 $ 1,743,427 $ 1,277,236
Derivative Liabilities	Derivative Liabilities The Company accounts for warrants determined to be derivative financial instruments by recording the warrants as a liability at fair value and marks-to-market the instruments at fair values as of each subsequent balance sheet date. Any change in fair value is recorded as a change in the fair value of derivative liabilities for each reporting period at each balance sheet date. The Company reassesses the classification at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. As of December 31, 2018 and 2017, the Company’s only derivative liabilities are warrants issued to the selling agent for its IPO in 2017.
Revenue Recognition	Revenue Recognition The Company derives revenue primarily from the sale of its products to O&P providers, the VA, rehabilitation hospitals, and through distributors. Recently, the Company has begun providing devices directly to patients and billing their insurance companies directly, utilizing the clinical services of O&P providers for which they are paid a fee. The Company recognizes revenue upon shipment, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance, the sales price is fixed or The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of certain new or revised financial accounting standards until they would apply to private companies. As such, we have delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. The Company receives federally-funded grants that require the Company to perform research activities as specified in each respective grant. The Company is paid based on the fees stipulated in the respective grants which approximate the projected costs to be incurred by the Company to perform such activities. The Company’s grant revenue is recognized when persuasive evidence of the arrangement exists, the service has been provided and adherence to specific parameters of the awarded grant have been met, the amount is fixed and determinable and collection is reasonable assured. The Company recognized approximately $64,600 and $118,100, respectively, of grant income in 2018 and 2017, respectively. Direct costs related to these grants are reported as a component of research and development costs in the statements of operations except for reimbursable costs which are reported as a component of cost of revenue in the statements of operations. Cost of revenue includes reimbursable costs of approximately $31,600 and $11,600 in 2018 and 2017, respectively. Amounts received in advance are deferred.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs paid by customers are netted against the related shipping costs we incur. The net cost is recorded in cost of sales. Historically, such costs have not been material.
Income Taxes	Income Taxes The Company accounts for income taxes under Accounting Standards Codification ASC 740 Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. ASC 740 requires that the tax effects of changes in tax laws or rates be recognized in the financial statement in the period in which the law is enacted. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company’s financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company’s financial condition, results of operations or cash flows. The Company files income tax returns in federal and state jurisdictions and is no longer subject to examinations by tax authorities for years prior to 2015. Currently, there are no income tax audits in process.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock awards to employees by measuring the cost of services received in exchange for the award of equity instruments based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award. Options and warrants granted to consultants and other non-employees are recorded at fair value as of the grant date and subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Stock-based compensation expense of approximately $814,700 and $279,500 was recorded in research and development, selling, general and administrative expense in 2018 and 2017, respectively.
Net Loss per Share	Net Loss per Share Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Convertible debt, preferred stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the years ended December 31, 2018 and 2017, respectively, and as a result, all potentially dilutive common shares are considered antidilutive for these periods. Potentially common shares issuable at December 31, 2018 and 2017 consist of: 2018 2017 Options 723,744 369,004 Warrants 5,071,887 6,277,443 Restricted stock units 38,125 — Restricted stock 38,269 — Total 5,872,025 6,646,447
Advertising	Advertising The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $136,300 and $31,000 in 2018 and 2017, respectively.
Research and Development Costs	Research and Development Costs The Company expenses research and development costs as incurred. Research and development costs primarily consist of salaries and benefits, facility and overhead costs, and outsourced research activities.
Reclassification	Reclassification Certain prior period amounts included in the statement of cash flows for the year ended December 31, 2017 have been reclassified to conform to the current year’s presentation in accordance with ASU 2017-18. See “Recent Accounting Pronouncements.”
Subsequent Events	Subsequent Events The Company evaluates events and/or transactions occurring after the balance sheet date and before the issue date of the financial statements to determine if any of those events and/or transactions require adjustment to or disclosure in the financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Related Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers: Topic 606,” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 — Revenue Recognition and most industry-specific guidance throughout the ASC. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In March 2016, the FASB issued ASU No. 2016-08, “Revenue from Contracts with Customers—Principal versus Agent Considerations.” This update provides clarifying guidance regarding the application of ASU No. 2014-09 — Revenue from Contracts with Customers when another party, along with the reporting entity, is involved in providing a good or a service to a customer. In these circumstances, an entity is required to determine whether the nature of its promise is to provide that good or service to the customer (that is, the entity is a principal) or to arrange for the good or service to be provided to the customer by the other party (that is, the entity is an agent). The amendments in the Update clarify the implementation guidance on principal versus agent considerations. In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2016-12”). ASU 2016-12 provides clarifying guidance in a few narrow areas and adds some practical expedients to the guidance. In September 2017, the FASB issued ASU No. 2017-13, “Revenue Recognition (Topic 605) and Revenue from Contracts with Customers (Topic 606). The Company qualifies as an “emerging growth company” as defined in the JOBS Act. An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include an exemption from the adoption of certain new or revised financial accounting standards until they would apply to private companies. As such, the Company delayed the adoption of Accounting Standards Codification (“ASC”) No. 606, Revenue from Contracts with Customers until January 1, 2019. The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). The Company is adopting ASU No 2016-08 and related ASC 606 amendments effective January 1, 2019 using the modified retrospective method. Based on the results of the Company’s assessment to date, this standard did not have a material impact on the Company’s financial statements for 2018 and is not expected to have a material impact in future years. The Company will enhance its revenue recognition disclosures, as required by this standard, including significant judgments and practical expedients used by the Company in applying the five-step revenue model. The cumulative impact to the Company’s accumulated deficit as of December 31, 2018 is expected to be de minimums. Other Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. As an emerging growth company, the Company expects to delay adoption of ASU 2016-02 until January 1, 2020. ASU 2016-02 is not expected to have a material impact on the financial statements or disclosures. In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This update simplifies several aspects of the accounting for share-based payment awards, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The update is effective for fiscal years beginning after December 15, 2017, including interim periods. The Company adopted this standard effective January 1, 2018, using a modified retrospective transition approach, which requires that the cumulative effect of initially applying the standard to be recorded as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application. We elected to no longer calculate an estimate of expected forfeitures and began recognizing forfeitures as they occur. The cumulative-effect adjustment to accumulated deficit at January 1, 2018 was immaterial. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,” which addresses the diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows with respect to eight specific cash flow issues. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The amendments should be applied using a retrospective transition method to each In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)”, which clarifies how entities should present restricted cash and restricted cash equivalents in the statement of cash flows, and as a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. An entity with a material balance of restricted cash and restricted cash equivalents must disclose information about the nature of the restrictions. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted and the new guidance must be applied retroactively to all periods presented. The adoption of this standard did not have a material impact to the financial statements or disclosures. In May 2017, the FASB issued ASU No. 2017-09, Compensation — Stock Compensation (Topic 718); Scope of Modification Accounting. The amendments in this ASU provide guidance that clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. If the value, vesting conditions or classification of the award changes, modification accounting will apply. The guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of this standard did not have a material impact to the financial statements or disclosures. In July 2017, the FASB issued ASU No. 2017-11, which changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU No. 2017-11 also clarifies existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. ASU No. 2017-11 requires entities to recognize the effect of the down round feature in a freestanding equity-classified financial instrument only when it is triggered. The effect of triggering such a feature will be recognized as a dividend and a reduction to income available to common shareholders in basic. ASU No. 2017-11 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts ASU No. 2017-11 in an interim period, adjustments should be reflected as of the beginning of the interim period in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which ASU No. 2017-11 is effective or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. During the fourth quarter of 2017, we early adopted ASU No. 2017-11. The early adoption of ASU 2017-11 resulted in the warrants issued in conjunction with our December 2017 FPO, which contain the aforementioned down-round feature, being accounted for as an equity instrument rather than a derivative liability. In June 2018, the FASB issued ASU No. 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” The ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company is currently evaluating the accounting, transition, and disclosure requirements of the standard to determine the impact, if any, on its financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” The ASU requires application of the prospective method of transition (for only the most recent interim or annual period presented in the initial fiscal year of adoption) to the new disclosure requirements for (1) changes in unrealized gains and losses included in OCI and (2) the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The ASU also requires prospective application to any modifications to disclosures made because of the change to the requirements for the narrative description of measurement uncertainty. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. The Company is currently evaluating the accounting, transition, and disclosure requirements of the standard to determine the impact, if any, on its financial statements. Subsequent Events The Company evaluated subsequent events through the date the financial statements were issued, and determined that, except as disclosed herein, there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the balance sheets that sum to the total of the same amounts show in the statement of cash flows. 2018 2017 Cash and cash equivalents $ 6,540,794 $ 12,959,373 Restricted cash 75,000 52,000 Total cash, cash equivalents, and restricted cash in the balance sheet $ 6,615,794 $ 13,011,373
Summary of Accounts Payable and Other Accrued Expenses	Accounts Payable and Other Accrued Expenses: 2018 2017 Trade payables $ 426,727 $ 264,890 Accrued compensation and benefits 1,027,757 642,425 Accrued directors fees — 100,000 Other 288,943 269,921 $ 1,743,427 $ 1,277,236
Summary of Potentially Common Shares Issuable	Potentially common shares issuable at December 31, 2018 and 2017 consist of: 2018 2017 Options 723,744 369,004 Warrants 5,071,887 6,277,443 Restricted stock units 38,125 — Restricted stock 38,269 — Total 5,872,025 6,646,447

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following at December 31: 2018 2017 Finished goods $ 146,640 $ 122,000 Consigned inventory 135,635 97,980 Parts and components 48,874 23,530 331,149 243,510 Less: excess and obsolete inventory reserves (24,000 ) (23,739 ) Less: consigned inventory reserves (51,000 ) (18,616 ) Inventories, net $ 256,149 $ 201,155

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Schedule of Equipment	Equipment consists of the following at December 31: 2018 2017 Computer equipment $ 76,424 $ 32,257 Sales demonstration units 155,293 54,003 R&D tools and molds 52,644 22,650 Furniture and fixtures 3,270 — 287,631 108,910 Less: accumulated depreciation (100,118 ) (31,760 ) Equipment, net $ 187,513 $ 77,150

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Schedule of Cash Equivalents and Derivative Liabilities Measured at Fair Value on Recurring Basis	Cash equivalents and derivative liabilities (see Note 10) measured at fair value on a recurring basis at December 31, 2018 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2018 Total Cash equivalents $ 6,037,456 — — $ 6,037,456 Common stock warrant liabilities — — $ 3,661 $ 3,661 Cash equivalents and derivative liabilities (see Note 10) measured at fair value on a recurring basis at December 31, 2017 were as follows: In Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2017 Total Cash equivalents $ 10,459,435 — — $ 10,459,435 Common stock warrant liabilities — — $ 39,930 $ 39,930
Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured	The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the year ended December 31, 2018 and 2017: Common stock warrant liability Balance – January 1, 2017 $ — Fair value of common stock warrant issued 156,725 Change in fair value of derivative liabilities (116,795 ) Balance – December 31, 2017 39,930 Change in fair value of derivative liabilities (36,269 ) Balance – December 31, 2018 $ 3,661
Significant Unobservable Inputs (Level 3) [Member]
Schedule of Fair Value Assumptions	Assumptions utilized in the valuation of Level 3 liabilities at December 31, were as follows: 2018 2017 Risk-free interest rate 2.51% 2.20% Expected life 3.44 years 4.44 years Expected volatility of underlying stock 62% 63% Expected dividend yield — —

Stock Award Plans and Stock-b_2

Stock Award Plans and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	Stock option activity under the Stock Option Plans during the years ended December 31, 2018 and 2017 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Life (years) Intrinsic Value Balance at January 1, 2017 246,344 $ 0.5133 7.10 $ 132,121 Granted 210,600 2.6568 Forfeited or cancelled (7,855 ) 0.9717 Exercised (80,085 ) 0.3366 Balance at December 31, 2017 369,004 1.7652 8.65 $ 732,399 Granted 375,186 3.0700 Forfeited or cancelled (13,632 ) 3.1100 Expired (5,642 ) 1.6900 Exercised (1,172 ) 3.8700 Balance at December 31, 2018 723,744 $ 2.4200 8.51 $ 157,260 Options exercisable at December 31, 2017 141,847 $ 0.6906 5.68 $ 99,879 Options exercisable at December 31, 2018 336,718 $ 1.9500 7.74 $ 141,506
Schedule of Grant Date Fair Value	The assumptions underlying the calculation of grant date fair value are as follows: 2018 2017 Volatility 60.00%-61.96% 62.71%-80.00% Risk-free interest rate 2.65%-3.17% 0.58%-2.29% Weighted-average expected option term (in years) 6.25-9.92 5.75-6.25 Dividend yield 0% 0%
Summary of Restricted Stock Activity	Restricted stock activity for the years ended December 31, 2018 and 2017 is summarized below: Number of Shares Weighted average grant date fair value Weighted average remaining contractual life (in years) Outstanding as January 1, 2017 — $ — — Awarded 46,500 6.75 Vested (312 ) 6.75 Canceled (2,000 ) 6.75 Outstanding as December 31, 2017 44,188 6.75 6.75 Awarded 55,092 3.27 Vested (61,011 ) 4.83 Canceled — — Outstanding as of December 31, 2018 38,269 $ 4.80 1.39
Summary of Restricted Stock Unit Activity	Restricted stock unit activity for the year ended December 31, 2018 is summarized below: Number of Shares Weighted average grant date fair value Weighted average remaining contractual life (in years) Outstanding as of January 1, 2018 — — — Awarded 103,723 3.56 Vested (65,598 ) 3.68 Canceled — 3.35 Outstanding as of December 31, 2018 38,125 3.35 1.49
Schedule of Stock-based Compensation Expense	The Company recognized stock-based compensation expense related to the issuance of stock option awards to employees and non-employees and restricted stock awards to employees and directors, and restricted stock units to employees in the statements of operations as follow: 2018 2017 Research and development $ 103,457 $ 12,382 Selling, general and administrative 711,209 267,126 Total $ 814,666 $ 279,508

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Warrants And Rights Note Disclosure [Abstract]
Summary of Common Stock Warrants Activity	The following table presents the Company’s common stock warrant activity for the years ended December 31, 2018 and 2017: Warrants Weighted Average Exercise Price Outstanding Exercisable Outstanding Exercisable Balance, Jan 1, 2017 8,228 8,228 $ 6.47 $ 6.47 Issued 6,304,015 6,220,515 3.84 3.85 Exercised (34,800 ) (34,800 ) 2.95 2.95 Balance, Dec 31, 2017 6,277,443 6,193,943 3.85 3.86 Previously issued warrants which became exerciseable — 83,500 2.40 2.40 Issued — — — — Exercised (1,205,556 ) (1,205,556 ) 2.95 2.95 Balance, Dec 31, 2018 5,071,887 5,071,887 $ 4.05 $ 4.05

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Amounts Due under Agreement	The future minimum amounts due under this agreement for the next five years are as follows: 2019 $ 25,000 2020 25,000 2021 25,000 2022 25,000 2023 (year patents expire) 25,000
Summary of Changes in Warranty Liability	Changes in warranty liability were as follows: 2018 2017 Accrued warranty liability, beginning of year $ 50,725 $ 63,147 Accrual provided for warranties issued during the period 23,452 14,867 Adjustments to prior accruals 38,382 570 Actual warranty expenditures (20,559 ) (27,859 ) Accrued warranty liability, end of year $ 92,000 $ 50,725

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Summary of Tax Provision (Benefit)	The income tax provision (benefit) for the years ended December 31, 2018 and 2017 consist of the following: 12/31/18 12/31/17 U.S. federal Current $ — $ — Deferred (2,065,000 ) (534,000 ) State and local Current — — Deferred (571,000 ) (538,000 ) (2,636,000 ) (1,072,000 ) Deferred tax expense related to tax law change — 2,909,000 Change in valuation allowance 2,636,000 (1,837,000 ) Income tax provision $ — $ —
Summary of Reconciliation between U.S. Statutory Federal Income Tax Rate and Effective Rate	The reconciliation between the U.S statutory federal income tax rate and the Company’s effective rate for the years ended December 31, 2018 and 2017 is as follows: 12/31/18 12/31/17 U.S. federal statutory rate 21.00 % 34.00 % State income taxes, net of federal benefit 5.57 % 4.67 % Federal rate change, deferred items 0.00 % (23.03 )% State rate change and other (0.03 )% 0.89 % Non-deductible interest 0.00 % (17.67 )% Federal NOLs to expire unutilized due to sec 382 limitation 0.00 % (14.02 )% Other permanent items (0.98 )% (0.03 )% Change in valuation allowance (25.56 )% 15.19 % Effective rate 0.00 % 0.00 %
Summary of Deferred Tax Assets	As of December 31, 2018, and 2017, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: 12/31/18 12/31/17 Net operating loss carryover $ 8,378,000 $ 5,925,000 Tax credits 178,000 190,000 Stock-based compensation 27,000 53,000 Other 440,000 219,000 Total deferred tax asset 9,023,000 6,387,000 Less: valuation allowance (9,023,000 ) (6,387,000 ) Deferred tax asset, net of valuation allowance $ — $ —

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)		Dec. 06, 2017	Dec. 04, 2017	Jun. 09, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Organization Consolidation and Presentation of Financial Statements [Line Items]
Initial public offering raising amount	[1]					$ 4,368,315
Aggregate proceeds offering expenses						$ 2,922,885
Combined aggregate gross proceeds raised				$ 7,916,620
Authorized issue of shares				125,000,000
Common stock, shares authorized				100,000,000	100,000,000	100,000,000
Common stock, par value				$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized				25,000,000	25,000,000	25,000,000
Preferred stock, par value				$ 0.0001	$ 0.0001	$ 0.0001
Warrants to purchase common stock outsatanding					5,071,887	6,277,443	8,228
Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Other offering expenses				$ 1,061,157
Sale of stock				665,498
IPO [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Initial public offering raising amount				$ 4,991,235
Other offering expenses				$ 1,061,157
Sale of stock				665,498
Sale of common stock price per share				$ 7.50
IPO [Member] | Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Stock issued during period						665,498
Private Placement [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Other offering expenses				$ 2,500
Sale of stock				557,216
Sale of common stock price per share				$ 5.25
Share unit, description					Each unit consisted of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share.
Common stock warrants, exercise price per share				$ 7.50
Warrant expiration period				3 years
Aggregate proceeds offering expenses				$ 2,925,385
FPO [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Warrants to purchase common stock			4,175,000
Warrants to purchase common stock outsatanding					3,560,894
Warrant expiration date					Dec. 4, 2022
FPO [Member] | Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Sale of common stock price per share			$ 2.40
Common stock warrants, exercise price per share					$ 2.95
Stock issued during period			4,175,000
FPO [Member] | Common Stock and Warrants [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Sale of common stock price per share		$ 2.40
Stock issued during period		626,250
Over-allotment Option [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Other offering expenses		$ 1,115,000
Stock issued during period		4,801,250	4,801,250
Warrants to purchase common stock		4,801,250	4,801,250
Warrant expiration date		Dec. 4, 2022
Proceeds from sale of common stock		$ 11,523,000
Over-allotment Option [Member] | Common Stock [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Common stock warrants, exercise price per share		$ 2.95
Stock issued during period						4,801,250
[1]	IPO gross proceeds of $4,991,236 are reduced by $622,921 of IPO offering costs that were incurred in 2017. Another $438,237 of IPO deferred offering costs were paid for in 2016.

Going Concern and Management'_2

Going Concern and Management's Plan - Additional Information (Detail) - USD ($)	Jul. 02, 2018	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2017
Going Concern and Managements Liquidity Plan [Line Items]
Net loss			$ 10,316,739	$ 12,097,479
Accumulated deficit			45,289,526	34,972,787
Cash used in operating activities			$ 9,606,310	6,153,419
Proceeds from FPO, net of offering costs				$ 10,407,706
Maximum [Member]
Going Concern and Managements Liquidity Plan [Line Items]
Aggregate public offering price	$ 75,000,000
Maximum [Member] | Sales Agreement with B. Riley FBR, Inc. [Member]
Going Concern and Managements Liquidity Plan [Line Items]
At-the-market offering price	$ 15,000,000
At-the-market offering, agent's commission as percent	3.00%
Subsequent Event [Member]
Going Concern and Managements Liquidity Plan [Line Items]
Proceeds from FPO, net of offering costs		$ 5,600,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Summary of Significant Accounting Policies [Line Items]
Allowance for doubtful accounts		$ 0
Equipment estimated useful lives	3 years
Impairment charges	$ 0	0
Reimbursable costs	$ 31,600	11,600
Measurement of tax benefit, minimum likelihood of the largest amount being realized upon ultimate resolution	50.00%
Stock-based compensation expense	$ 814,666	279,508
Advertising expense	136,300	31,000
Selling, General and Administrative Expenses [Member]
Summary of Significant Accounting Policies [Line Items]
Demonstration units, expenses	256,700	26,900
Stock-based compensation expense	711,209	267,126
Research and Development Expense [Member]
Summary of Significant Accounting Policies [Line Items]
Test units, expenses	17,700	29,200
Stock-based compensation expense	103,457	12,382
Grant Income [Member]
Summary of Significant Accounting Policies [Line Items]
Grant income recognized	$ 64,600	$ 118,100

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 6,540,794	$ 12,959,373
Restricted cash	75,000	52,000
Total cash, cash equivalents, and restricted cash in the balance sheet	$ 6,615,794	$ 13,011,373	$ 849,174

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Accounts Payable and Other Accrued Expenses (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Trade payables	$ 426,727	$ 264,890
Accrued compensation and benefits	1,027,757	642,425
Accrued directors fees		100,000
Other	288,943	269,921
Total	$ 1,743,427	$ 1,277,236

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Potentially Common Shares Issuable (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,872,025	6,646,447
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	723,744	369,004
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,071,887	6,277,443
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	38,125
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	38,269

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 146,640	$ 122,000
Consigned inventory	135,635	97,980
Parts and components	48,874	23,530
Total cost	331,149	243,510
Less: excess and obsolete inventory reserves	(24,000)	(23,739)
Less: consigned inventory reserves	(51,000)	(18,616)
Inventories, net	$ 256,149	$ 201,155

Equipment - Schedule of Equipme

Equipment - Schedule of Equipment (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 287,631	$ 108,910
Less: accumulated depreciation	(100,118)	(31,760)
Equipment, net	187,513	77,150
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	76,424	32,257
Sales Demonstration Units [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	155,293	54,003
R&D Tools and Molds [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	52,644	$ 22,650
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 3,270

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Cash Equivalents and Derivative Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 6,037,456	$ 10,459,435
Common stock warrant liabilities	3,661	39,930
In Active Markets for Identical Assets or Liabilities (Level 1) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	6,037,456	10,459,435
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Common stock warrant liabilities	$ 3,661	$ 39,930

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value Reconciliation of Level 3 Liabilities Measured (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Beginning balance	$ 39,930
Fair value of common stock warrant issued		$ 156,725
Change in fair value of derivative liabilities	(36,269)	(116,795)
Ending balance	$ 3,661	$ 39,930

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Schedule of Assumptions Utilized in Valuation of Level 3 Liabilities (Detail)	Dec. 31, 2018	Dec. 31, 2017
Risk-free Interest Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	2.51	2.20
Expected Life [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	3.44	4.44
Expected Volatility of Underlying Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	62	63
Expected Dividend Yield [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value assumptions	0	0

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	Jul. 02, 2018	Dec. 06, 2017	Dec. 04, 2017	Nov. 13, 2017	Jun. 09, 2017	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Aggregate proceeds offering expenses								$ 2,922,885
Authorized issue of shares					125,000,000
Common stock, shares authorized					100,000,000		100,000,000	100,000,000
Common stock, par value					$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized					25,000,000		25,000,000	25,000,000
Preferred stock, par value					$ 0.0001		$ 0.0001	$ 0.0001
Warrants to purchase common stock outsatanding							5,071,887	6,277,443	8,228
Common stock issued for the exercise of warrants							$ 3,556,391	$ 102,660
Repayment of outstanding principal and accrued interest				$ 1,081,135				$ 1,215,900
Common stock shares issued							12,450,187	11,139,667
Common stock issued for the exercise of common stock options, shares							1,172	80,085
Proceeds from exercise of stock options							$ 2	$ 26,954
Net withheld for employee taxes							22,819
80% of Share Price on Repayment Date [Member]
Class of Stock [Line Items]
Common stock shares price per share				$ 5.03
Common stock shares issued				107,505
20% Share Price on Repayment Date [Member]
Class of Stock [Line Items]
Common stock shares price per share				$ 6.29
Common stock shares issued				86,004
Maximum [Member]
Class of Stock [Line Items]
Aggregate public offering price	$ 75,000,000
Convertible Promissory Notes 2016 [Member]
Class of Stock [Line Items]
Accrued but unpaid interest, total					$ 5,467,389
Convertible common stock, shares					1,055,430
Weighted average price per share					$ 5.18
Sales Agreement with B. Riley FBR, Inc. [Member] | Maximum [Member]
Class of Stock [Line Items]
At-the-market offering price	$ 15,000,000
At-the-market offering, agent's commission as percent	3.00%
Private Placement [Member]
Class of Stock [Line Items]
Other offering expenses					$ 2,500
Sale of stock					557,216
Common stock shares price per share					$ 5.25
Aggregate proceeds offering expenses					$ 2,925,385
Warrant expiration period					3 years
Common stock warrants, exercise price per share					$ 7.50
Share unit, description							Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share.
FPO [Member]
Class of Stock [Line Items]
Warrants to purchase common stock			4,175,000
Warrants to purchase common stock outsatanding							3,560,894
Warrant expiration date							Dec. 4, 2022
Common stock issued for the exercise of warrants, shares							1,205,556	34,800
Common stock issued for the exercise of warrants							$ 3,556,000	$ 102,660
Over-allotment Option [Member]
Class of Stock [Line Items]
Other offering expenses		$ 1,115,000
Stock issued during period		4,801,250	4,801,250
Warrants to purchase common stock		4,801,250	4,801,250
Warrant expiration date		Dec. 4, 2022
Proceeds from sale of common stock		$ 11,523,000
Fair value of stock issued								$ 10,407,706
Common Stock [Member]
Class of Stock [Line Items]
Common stock raising					$ 4,991,235
Other offering expenses					$ 1,061,157
Sale of stock					665,498
Sale of stock price per share					$ 7.50
Convertible common stock, shares								1,055,430
Common stock issued for the exercise of warrants, shares							1,205,556	34,800
Common stock issued for the exercise of warrants							$ 121	$ 3
Shares issued for services								4,000
Common stock issued for the exercise of common stock options, shares							1,172	80,085
Proceeds from exercise of stock options							$ 2	$ 26,954
Common stock issued upon vesting of restricted stock units, Shares							42,781
Net withheld for employee taxes							61,011	312
Common Stock [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Common stock issued upon vesting of restricted stock units, Shares							42,781
Net withheld for employee taxes							22,819
Common Stock [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Common stock issued upon vesting of restricted stock units, Shares							61,011	312
Common Stock [Member] | Accredited Investors [Member]
Class of Stock [Line Items]
Sale of stock on a private placement , description							The Company also closed on a private placement pursuant to which it sold to accredited investors an aggregate of 557,216 units at $5.25 per unit, for aggregate proceeds of $2,925,385, before offering expenses of $2,500. Each unit consists of one share of common stock and a three-year warrant to purchase one share of common stock exercisable for $7.50 per share.
Common Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Shares issued for services						4,000
Fair value of stock issued						$ 30,000
Common Stock [Member] | FPO [Member]
Class of Stock [Line Items]
Common stock shares price per share			$ 2.40
Common stock warrants, exercise price per share							$ 2.95
Stock issued during period			4,175,000
Common Stock [Member] | Over-allotment Option [Member]
Class of Stock [Line Items]
Common stock warrants, exercise price per share		$ 2.95
Stock issued during period								4,801,250
Fair value of stock issued								$ 480
Common Stock and Warrants [Member] | FPO [Member]
Class of Stock [Line Items]
Common stock shares price per share		$ 2.40
Stock issued during period		626,250

Treasury Stock - Additional Inf

Treasury Stock - Additional Information (Detail) - shares	Dec. 31, 2018	Dec. 31, 2017
Treasury Stock Shares [Abstract]
Treasury stock, common, shares	808	808

Stock Award Plans and Stock-b_3

Stock Award Plans and Stock-based Compensation - Additional Information (Detail) - USD ($)	Jan. 01, 2019	Jul. 09, 2018	Jun. 19, 2018	Jan. 03, 2018	Jan. 02, 2018	Aug. 15, 2017	Oct. 25, 2016	Mar. 03, 2018	Dec. 31, 2018	Dec. 31, 2017	Apr. 01, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit recognized									$ 0	$ 0
weighted-average grant date fair value per share									$ 1.77	$ 1.62
Number of shares, granted										6,304,015
Common Stock [Member] | Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, granted			39,864	15,228
Compensation expense								$ 60,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted						46,500
Aggregate fair market value on the date of grant						$ 313,900
Compensation expense										$ 123,000
Number of shares, granted									55,092	46,500
Unrecognized compensation cost									$ 164,300
Weighted-average remaining contractual term									1 year 4 months 20 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense									$ 242,551
Number of shares, granted					88,723				103,723
Provisions for lapsing forfeiture rights extended period									24 months
Restricted Stock Units subject to forfeiture									23,123
Unrecognized compensation cost									$ 116,800
Weighted-average remaining contractual term									1 year 5 months 26 days
Restricted Stock Units (RSUs) [Member] | Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Restricted Stock Units (RSUs) [Member] | Officer [Member] | Vest in Full on the First Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, granted		5,000
Restricted Stock Units (RSUs) [Member] | Officer [Member] | Vest Over Four Years [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, granted		10,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost									$ 586,600
Weighted-average remaining contractual term									2 years 1 month 28 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period									4 years
Minimum [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period									10 years
Maximum [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						5 months
Subsequent Event [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	156
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	91,368
2018 Stock Options and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grant			706,119						505,153
Percentage increase in number of shares of common stock reserved and available for issuance			4.00%
2018 Stock Options and Incentive Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common shares reserved for issuance	620,000
2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grant											86,119
Number of common shares reserved for issuance							562,500
Additional awards granted							0

Stock Award Plans and Stock-b_4

Stock Award Plans and Stock-based Compensation - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares, Beginning balance	369,004	246,344
Shares, Granted	375,186	210,600
Shares, Forfeited or cancelled	(13,632)	(7,855)
Shares, Expired	(5,642)
Shares, Exercised	(1,172)	(80,085)
Shares, Ending balance	723,744	369,004	246,344
Shares, Options exercisable	336,718	141,847
Weighted average exercise price, Beginning balance	$ 1.7652	$ 0.5133
Weighted average exercise price, Granted	3.0700	2.6568
Weighted average exercise price, Forfeited or cancelled	3.1100	0.9717
Weighted average exercise price, Expired	1.6900
Weighted average exercise price, Exercised	3.8700	0.3366
Weighted average exercise price, Ending balance	2.4200	1.7652	$ 0.5133
Weighted average exercise price, Options exercisable	$ 1.9500	$ 0.6906
Weighted average remaining life	8 years 6 months 3 days	8 years 7 months 24 days	7 years 1 month 6 days
Weighted average remaining life, Options exercisable	7 years 8 months 26 days	5 years 8 months 4 days
Intrinsic value, Beginning balance	$ 732,399	$ 132,121
Intrinsic value, Ending balance	157,260	732,399	$ 132,121
Intrinsic value, Options exercisable	$ 141,506	$ 99,879

Stock Award Plans and Stock-b_5

Stock Award Plans and Stock-based Compensation - Schedule of Grant Date Fair Value (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Option Indexed to Issuer's Equity [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Option Indexed to Issuer's Equity [Line Items]
Volatility	60.00%	62.71%
Risk-free interest rate	2.65%	0.58%
Weighted-average expected option term (in years)	6 years 3 months	5 years 9 months
Maximum [Member]
Option Indexed to Issuer's Equity [Line Items]
Volatility	61.96%	80.00%
Risk-free interest rate	3.17%	2.29%
Weighted-average expected option term (in years)	9 years 11 months 1 day	6 years 3 months

Stock Award Plans and Stock-b_6

Stock Award Plans and Stock-based Compensation - Summary of Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Awarded		6,304,015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding, beginning balance	44,188
Number of shares, Awarded	55,092	46,500
Number of shares, Vested	(61,011)	(312)
Number of shares, Canceled		(2,000)
Number of shares outstanding, ending balance	38,269	44,188
Weighted average grant date fair value outstanding, beginning balance	$ 6.75
Weighted average grant date fair value, Awarded	3.27	$ 6.75
Weighted average grant date fair value, Vested	4.83	6.75
Weighted average grant date fair value, Canceled		6.75
Weighted average grant date fair value outstanding, ending balance	$ 4.80	$ 6.75
Weighted average remaining contractual life	1 year 4 months 20 days	6 years 9 months

Stock Award Plans and Stock-b_7

Stock Award Plans and Stock-based Compensation - Summary of Restricted Stock Unit Activity (Detail) - $ / shares	Jan. 02, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Awarded			6,304,015
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares outstanding, beginning balance
Number of shares, Awarded	88,723	103,723
Number of shares, Vested		(65,598)
Number of shares outstanding, ending balance		38,125
Weighted average grant date fair value outstanding, beginning balance
Weighted average grant date fair value, Awarded		$ 3.56
Weighted average grant date fair value, Vested		3.68
Weighted average grant date fair value, Canceled		3.35
Weighted average grant date fair value outstanding, ending balance		$ 3.35
Weighted average remaining contractual life		1 year 5 months 26 days

Stock Award Plans and Stock-b_8

Stock Award Plans and Stock-based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 814,666	$ 279,508
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	103,457	12,382
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share based compensation expense	$ 711,209	$ 267,126

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($)	Dec. 06, 2017	Dec. 04, 2017	Jun. 09, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Warrants outstanding purchase of common stock, Shares			557,216
Warrants exercisable price per share			$ 7.50
Warrants are fully vested, exercise price			$ 8.25
Fair value of the warrants derivative liability			$ 156,725		$ 39,930
Warrants to purchase common stock outsatanding				5,071,887	6,277,443	8,228
Exercise price of warrants		$ 1.40
Weighted average remaining life, Options exercisable				7 years 8 months 26 days	5 years 8 months 4 days
Warrants [Member]
Class of Warrant or Right [Line Items]
Weighted average remaining life, Options exercisable				3 years 2 months 23 days
IPO Selling Agent [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants issued			33,275
FPO [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants issued		4,175,000
Warrant expiration date				Dec. 4, 2022
Warrants to purchase common stock		4,175,000
Warrants to purchase common stock outsatanding				3,560,894
FPO [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Common stock warrants, exercise price per share				$ 2.95
Stock issued during period		4,175,000
FPO [Member] | Common Stock and Warrants [Member]
Class of Warrant or Right [Line Items]
Stock issued during period	626,250
Over-allotment Option [Member]
Class of Warrant or Right [Line Items]
Warrant expiration date	Dec. 4, 2022
Stock issued during period	4,801,250	4,801,250
Warrants to purchase common stock	4,801,250	4,801,250
Over-allotment Option [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Common stock warrants, exercise price per share	$ 2.95
Stock issued during period					4,801,250
Underwriters Follow on Public Offering [Member]
Class of Warrant or Right [Line Items]
Warrants years of life		3 years
Purchase of warrants issued		83,500
Warrants are fully vested, exercise price		$ 2.40
2016 Convertible Promissory Notes [Member] | IPO [Member]
Class of Warrant or Right [Line Items]
Warrants years of life			3 years
Convertible Promissory Notes 2015 [Member] | IPO [Member]
Class of Warrant or Right [Line Items]
Warrants years of life			5 years

Warrants - Summary of Common St

Warrants - Summary of Common Stock Warrants Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Warrants outstanding, beginning balance	6,277,443	8,228
Warrants outstanding, issued		6,304,015
Warrants outstanding, exercised	(1,205,556)	(34,800)
Warrants outstanding, ending balance	5,071,887	6,277,443
Warrants exercisable, beginning balance	6,193,943	8,228
Warrants exercisable, previously issued warrants which became exerciseable	83,500
Warrants exercisable, issued		6,220,515
Warrants exercisable, exercised	(1,205,556)	(34,800)
Warrants exercisable, ending balance	5,071,887	6,193,943
Weighted average exercise price outstanding, beginning balance	$ 3.85	$ 6.47
Weighted average exercise price outstanding, previously issued warrants which became exerciseable	2.40
Weighted average exercise price outstanding, issued		3.84
Weighted average exercise price outstanding, exercised	2.95	2.95
Weighted average exercise price outstanding, ending balance	4.05	3.85
Weighted average exercise price exercisable, beginning balance	3.86	6.47
Weighted average exercise price exercisable, previously issued warrants which became exerciseable	2.40
Weighted average exercise price exercisable, issued		3.85
Weighted average exercise price exercisable, exercised	2.95	2.95
Weighted average exercise price exercisable, ending balance	$ 4.05	$ 3.86

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Dec. 04, 2017	Jun. 09, 2017	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Revenue recognized from related party			$ 306,200	$ 53,500
Due for related parties			0
Accounts receivable				77,600
Charges for services			$ 530,300	$ 356,400
Type of Cost, Good or Service [Extensible List]			us-gaap:ServiceMember	us-gaap:ServiceMember
Accounts payable and accrued expenses			$ 54,300	$ 65,800
Private Placement [Member]
Related Party Transaction [Line Items]
Common stock warrants, exercise price per share		$ 7.50
Directors And Officers [Member]
Related Party Transaction [Line Items]
Stock issued during period	285,000	14,000
Share price	$ 2.40	$ 7.50
Warrants to purchase common stock	285,000
Common stock warrants, exercise price per share	$ 2.95
Directors And Officers [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Stock issued during period		125,238
Share price		$ 5.25
Warrants to purchase common stock		125,238
Common stock warrants, exercise price per share		$ 7.50

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Dec. 29, 2017shares	Dec. 31, 2018USD ($)Customershares	Dec. 31, 2017USD ($)Customer	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Rent expense		$ 352,800	$ 221,200
Proceeds from issuance of common stock			$ 10,407,706
Product warranty period		3 years		1 year
Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Number of customers | Customer		2	3
Accounts Receivable
Commitments And Contingencies [Line Items]
Number of customers | Customer		2	3
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage		25.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			23.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			17.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Three Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			14.00%
Customer Concentration Risk [Member] | Accounts Receivable
Commitments And Contingencies [Line Items]
Concentration risk, percentage			55.00%
Customer Concentration Risk [Member] | Accounts Receivable | One Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage		20.00%
Customer Concentration Risk [Member] | Accounts Receivable | Two Customers [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage		16.00%
Due From Related Party [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage		13.00%
Due From Related Party [Member] | Customer Concentration Risk [Member] | Accounts Receivable | One Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			26.00%
Due From Related Party [Member] | Customer Concentration Risk [Member] | Accounts Receivable | Two Customers [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			18.00%
Due From Related Party [Member] | Customer Concentration Risk [Member] | Accounts Receivable | Three Customer [Member]
Commitments And Contingencies [Line Items]
Concentration risk, percentage			11.00%
Licensing Agreements [Member]
Commitments And Contingencies [Line Items]
Minimum sales covenant		$ 750,000
Licensing Agreements [Member] | MIT [Member]
Commitments And Contingencies [Line Items]
Stock issued during period | shares	492	6,172
Minimum percentage of outstanding common stock to be maintained		1.00%
Proceeds from issuance of common stock		$ 3,000,000
Licensing Agreements [Member] | Cost of Sales [Member]
Commitments And Contingencies [Line Items]
Royalty charge		$ 49,300	$ 25,000

Commitments and Contingencies_2

Commitments and Contingencies - Future Minimum Amounts Due under Agreement (Detail) - Licensing Agreements [Member]	Dec. 31, 2018USD ($)
Finite Lived Intangible Assets [Line Items]
2019	$ 25,000
2020	25,000
2021	25,000
2022	25,000
2023 (year patents expire)	$ 25,000

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Changes in Warranty Liability (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Product Warranties Disclosures [Abstract]
Accrual provided for warranties issued during the period Accrued warranty liability, beginning of year	$ 50,725	$ 63,147
Accrual provided for warranties issued during the period	23,452	14,867
Adjustments to prior accruals	38,382	570
Actual warranty expenditures	(20,559)	(27,859)
Accrued warranty liability, end of year	$ 92,000	$ 50,725

Income Taxes - Summary of Tax P

Income Taxes - Summary of Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
U.S. federal
Deferred	$ (2,065,000)	$ (534,000)
State and local
Deferred	(571,000)	(538,000)
Total	(2,636,000)	(1,072,000)
Deferred tax expense related to tax law change		2,909,000
Change in valuation allowance	$ 2,636,000	$ (1,837,000)

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation between U.S. Statutory Federal Income Tax Rate and Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
U.S. federal statutory rate	21.00%	34.00%
State income taxes, net of federal benefit	5.57%	4.67%
Federal rate change, deferred items	0.00%	(23.03%)
State rate change and other	(0.03%)	0.89%
Non-deductible interest	0.00%	(17.67%)
Federal NOLs to expire unutilized due to sec 382 limitation	0.00%	(14.02%)
Other permanent items	(0.98%)	(0.03%)
Change in valuation allowance	(25.56%)	15.19%
Effective rate	0.00%	0.00%

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Components Of Deferred Tax Assets [Abstract]
Net operating loss carryover	$ 8,378,000	$ 5,925,000
Tax credits	178,000	190,000
Stock-based compensation	27,000	53,000
Other	440,000	219,000
Total deferred tax asset	9,023,000	6,387,000
Less: valuation allowance	$ (9,023,000)	$ (6,387,000)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Deferred tax liabilities	$ 0	$ 0
Net operating loss carryforwards limitations	1,559,000
Operating loss carryforward unutilized	5,000,000
Valuation allowance on net operating loss carryforwards	$ 1,700,000
U.S. federal statutory rate	21.00%	34.00%
Change in valuation allowance	$ (2,636,000)	$ 1,837,000
Tax penalties and interest	0	0	$ 0
Accrued interest and penalties	0	$ 0
Tax Liability [Member]
Income Tax [Line Items]
Accrued interest and penalties	$ 0
Tax Cuts and Jobs Act (TCIA) [Member]
Income Tax [Line Items]
U.S. federal statutory rate	21.00%	35.00%
Valuation of deferred tax assets due to change in enacted tax rate		$ 2,909,000
Federal [Member]
Income Tax [Line Items]
Net operating loss	$ 35,519,000	26,425,000
Net operating loss beginning year	begin expiring in the year 2028
Federal [Member] | Tax Year 2018 [Member]
Income Tax [Line Items]
Net operating loss	$ 9,094,000
State [Member]
Income Tax [Line Items]
Net operating loss	$ 29,212,000	$ 22,046,000
Net operating loss beginning year	begin to expire in 2019 through 2027

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Feb. 18, 2019Installmentshares	Feb. 12, 2019USD ($)$ / sharesshares	Jan. 01, 2019$ / sharesshares	Dec. 30, 2017$ / shares	Dec. 04, 2017$ / shares	Aug. 15, 2017shares	Feb. 28, 2019USD ($)	Dec. 31, 2017$ / shares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Subsequent Event [Line Items]
Proceeds from FPO, net of offering costs | $										$ 10,407,706
Exercise price of warrants					$ 1.40
Restricted Stock [Member]
Subsequent Event [Line Items]
Shares of common stock issued upon vesting of stock awards | shares						46,500
Weighted average grant date fair value, Vested									$ 4.83	$ 6.75
Weighted average grant date fair value, Awarded									$ 3.27	$ 6.75
Restricted stock, vested | shares									61,011	312
Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Weighted average grant date fair value, Vested									$ 3.68
Weighted average grant date fair value, Awarded									$ 3.56
Restricted stock, vested | shares									65,598
2017 Warrants [Member]
Subsequent Event [Line Items]
Exercise price of warrants				$ 2.95				$ 1.40
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from FPO, net of offering costs | $							$ 5,600,000
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Shares of common stock issued upon vesting of stock awards | shares			156
Weighted average grant date fair value, Vested			$ 1.63
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Shares of common stock issued upon vesting of stock awards | shares			91,368
Weighted average grant date fair value, Awarded			$ 1.60
Vesting percentage	25.00%
Number of monthly installments for vesting | Installment	12
Restricted stock, vested | shares	20,000
Subsequent Event [Member] | Incentive Stock Option [Member]
Subsequent Event [Line Items]
Number of shares vested | shares	50,000
Vesting percentage	25.00%
Number of monthly installments for vesting | Installment	36
Subsequent Event [Member] | Underwriter Warrants [Member]
Subsequent Event [Line Items]
Warrants to purchase common stock | shares		363,400
Common stock warrants, exercise price per share		$ 1.75
Warrant exercisable period		6 months
Warrant expiration period		4 years
Underwritten Public Offering [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from offering costs, shares | shares		4,542,500
Sale of common stock price per share		$ 1.40
Proceeds from FPO, net of offering costs | $		$ 6,400,000